EGFR expression	Lung Non-Small Cell Squamous Cancer	EGFR expression	Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
EGFR expression	Chordoma	EGFR expression	Chordoma	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
EGFR expression	HER2 Positive Breast Cancer	EGFR expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR expression	Squamous Cell Carcinoma of Head and Neck	EGFR expression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1
EGFR expression	Salivary Gland Cancer	EGFR expression	Salivary Gland Cancer	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	osimertinib Sensitive: C2 – Inclusion Criteria osimertinib Sensitive : C2	osimertinib Sensitive: C2 – Inclusion Criteria osimertinib Sensitive : C2

EGFR expression

Associations